Date: 2012-02-17
Type of information: R&D agreement
Compound: biomarkers for the early detection of cancer (nucleosome-based diagnostic tests for lung, colorectal and pancreatic cancer)
Company: Abcodia (UK) VolitionRX (Singapore)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: lung cancer, colorectal cancer, pancreatic cancer
Details: Abcodia, a biomarker validation company, has announced a collaboration with life sciences company VolitionRx which will advance the development of biomarkers for the early detection of cancer. The partnership will discover and develop nucleosome-based diagnostic tests for lung, colorectal and pancreatic cancer by using the latest ground breaking technology.
Abcodia, a spin-out from University College London (UCL), will work closely with VolitionRx on the design of the programme and the identification of cohort samples from its large prospective serum biobank and, Volition Rx will use its expertise in developing blood-based diagnostic tests to produce the very latest and innovative nucleosome-based diagnostic tests for cancer.
Financial terms: Financial details were not disclosed.
Latest news:
